BridgeBio have significantly advanced the progress of the new therapy for ATTR-CM, leveraging the compound. Initial trial results indicates significant outcomes for those affected from this debilitating disease. This https://bridgebio012469.theobloggers.com/48766513/firm-advances-amyloidosis-management-using-the-therapy